Human LR3 IGF-I ELISA

Human LR³ insulin-like Growth Factor-I (LR³IGF-I) was developed by GroPep Bioreagents specifically for supplementation of mammalian cell culture to support the survival and proliferation of cells. It is engineered to have a higher biological potency than native IGF-I or IGF-II and has several advantages over recombinant insulin. Supplementation of cell cultures with LR³IGF-I at a much lower concentration results in equivalent or better productivity than supplementation with standard concentrations of insulin. LR³IGF-I is better able to stimulate the type I IGF receptor and thus induce a higher level of activation of intracellular signalling molecules, which are responsible for promoting cell survival by inhibition of apoptosis.This LR³IGF-I Rapid™ ELISA kit combines GroPep’s expertise in the field of IGF research and Biosensis’ newly established Rapid™ ELISA platform. This has resulted in the new LR³IGF-I Rapid™ ELISA kit, which provides for the sensitive, specific and reliable quantification of LR³IGF-I in less than 3 hours. The ELISA kit consists of a complete set of reagents and pre-coated plate to allow immediate assay of LR³IGF-I in culture media. Included in the kit are mouse monoclonal anti- LR³IGF-I capture antibody pre-coated onto an ELISA plate, standard LR³IGF-I protein, a biotinylated anti- LR³IGF-I detection antibody and horseradish peroxidase (HRP)-conjugated streptavidin. The addition of a substrate (3,3’,5,5’-tetramethylbenzidine, TMB) yields a coloured reaction product which is directly proportional to the concentration of LR³IGF-I present in samples and the supplied protein standard. This LR³IGF-I Rapid™ ELISA kit has been developed, optimized and validated to quantify LR³IGF-I in cell culture medium. It is likely to be used to measure LR³IGF-I in media and during downstream processing of media following a production cycle and is not intended for other use. This kit has been configured for research use only and is not to be used in diagnostic or clinical procedures.